Peptide half-life is the time for a specified measured amount or concentration to fall by half during the phase being described. It does not automatically tell you how long an effect lasts, how often a medicine is used or how long a laboratory solution remains stable.

If your question is about half-life in PRRT, the distinction is between radioactive decay, biological clearance and their combined effect. The short explanation below separates those meanings; the dedicated PRRT half-life guide covers the radiopharmaceutical context in more detail.

What does half-life mean in PRRT?

In peptide receptor radionuclide therapy, physical half-life describes radioactive decay. Biological half-life describes removal from the body or a specified compartment, considered separately from decay. Effective half-life combines decay and biological removal for the compartment and model being studied.

The IAEA radiopharmaceutical guidance, section 6.1.2, explains how physical decay and biological clearance contribute to a time–activity curve. A value for the radionuclide alone is therefore not automatically the same as the effective half-life measured in an organ. Neither number, on its own, states how long a clinical response lasts.

Half-life vs duration of action: four different questions

Scroll horizontally to read all columns.

TermWhat it describesWhat it does not establish
Elimination half-lifeA decline in the measured amount or concentration during a specified phase.The exact beginning or end of every effect.
Duration of actionHow long a defined effect persists under the measurement used.The chemical stability of a stored solution.
Formulation releaseHow material becomes available from a preparation over time.The molecule's clearance after release.
Shelf life or solution stabilityHow a product or sample changes under specified storage conditions.Its elimination from a biological system.

The practical question is: what is falling by half? A parent peptide in plasma, radioactivity in a tissue and an analytical signal from a stored sample are different quantities. The word “half-life” does not make those measurements interchangeable.

A simple peptide half-life calculation

For a single first-order decline, with absorption complete and no further input, the fraction remaining after a given time is (1/2)^(elapsed time ÷ half-life). Each complete half-life halves the amount remaining; it does not remove the same absolute amount each time.

Scroll horizontally to read all columns.

Half-lives elapsedAmount remaining from 100 arbitrary unitsPercentage remaining
0100100%
15050%
22525%
312.512.5%
46.256.25%
53.125About 3.1%

After five half-lives, this model leaves about 3.1% of the starting amount. It does not predict zero. More importantly, the table is arithmetic under stated assumptions: it is not a washout period, a preparation protocol or an instruction for using a medicine. Continued absorption, repeated input or several distribution phases can make a real concentration–time profile more complex.

Why the effect can last for a different time

The U.S. Wegovy prescribing information, section 12.3, reports a semaglutide elimination half-life of approximately one week. That is a pharmacokinetic measurement. It does not mean that weight, appetite or every other outcome resets at a seven-day boundary.

Clinical outcomes require their own measurements and follow-up. The semaglutide plateau guide, for example, examines weight trajectories over months and years. A trial's weight curve answers a different question from a plasma concentration curve.

Formulation matters too. The Sandostatin LAR label distinguishes octreotide pharmacokinetics from the release profile of its depot formulation. A slow-release preparation should not be described simply by copying an immediate-release half-life into a comparison chart. The octreotide and lanreotide comparison follows that formulation-specific distinction.

Why two published half-lives may differ

Before deciding that two reports disagree, check whether they measured the same molecule, formulation, sample and phase. A terminal estimate after the initial distribution phase may answer a different question from a short early sampling window. An assay for intact peptide may also differ from a measurement that includes related material.

Population and route belong beside the number. An estimate in a defined clinical study does not automatically establish a value for a different research material or experimental system. A useful comparison preserves those details rather than selecting the longer or shorter value without explanation.

A traceable statement reads: “In this study population, this formulation and route produced this measured half-life for this analyte under this model.” That sentence is more informative than a molecule name followed by a number.

Can half-life tell you a solution's shelf life?

A biological elimination estimate cannot supply a storage expiry date. Temperature, pH, light, container interactions and the analytical definition of stability belong to a separate experiment. A sample could retain one analytical attribute while another changes; “stable” needs a measurement and an acceptance criterion.

Use the peptide stability and degradation guide for that question. For any half-life claim, keep five details in view: the measured quantity, formulation, sample or population, sampling interval and model assumptions. Those details determine whether a number is relevant to the question you actually want to answer.